DBV Technologies S.A.
DBVT, DBVTF · Biological Products, (No Diagnostic Substances) · 296.0M shares · +21%/yr ↑ dilution · EDGAR filings ↗
Reference price $4.86 · est. market cap ~$1.4B — last insider sale, 2026-01-29 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — food-allergy clinical (Viaskin), heavy burn ($122M), funded.
Strengths
- Liquidity — current ratio 3.7 (46th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Net lossNet loss (net margin -2607.3%)
- Cash burnNegative free cash flow (-121.7M)
- Fund exitedNotable fund(s) exited this quarter: CITADEL ADVISORS LLC
- Chronic dilutionShare count +21%/yr over 3y (dilution, book value/share -51%)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-2609.2%
Net margin
-2607.3%
Return on equity
-87.1%
Return on assets
-62.9%
Revenue growth (QoQ)
39.5%
Current ratio
3.7×
Free cash flow
-$122M
EBITDA
-$144M
Tangible book value
$169M
Cash & investments
$194M
Cash runway
6q
Stock comp / revenue
95.6%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-01-29 | Mohideen Pharis | Sell | 534 | $4.86 |
| 2025-12-18 | EPIC Bpifrance | Sell | 1.3M | $4.19 |
| 2025-12-17 | EPIC Bpifrance | Sell | 2.0M | $4.84 |
| 2025-12-17 | EPIC Bpifrance | Sell | 40K | $5.28 |
| 2025-11-21 | Mohideen Pharis | Grant | 44K | — |
| 2025-11-21 | Mohideen Pharis | Sell | 1.6K | $2.77 |
| 2025-11-21 | Trapp Kevin Michael | Grant | 55K | — |
| 2025-11-21 | Boucinha Virginie | Grant | 32K | — |
| 2025-11-20 | Mohideen Pharis | Sell | 6.5K | $2.88 |
| 2025-07-29 | Mohideen Pharis | Sell | 464 | $2.22 |
| 2025-05-22 | Mohideen Pharis | Sell | 397 | $1.84 |
| 2025-01-30 | Mohideen Pharis | Sell | 600 | $0.85 |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-05 | Exec/director changeExhibits | filing ↗ |
| 2026-06-03 | 5.03Shareholder voteExhibits | filing ↗ |
| 2026-05-05 | Exec/director changeExhibits | filing ↗ |
| 2026-04-30 | ResultsExhibits | filing ↗ |
| 2026-03-26 | ResultsExhibits | filing ↗ |
| 2026-03-02 | OtherExhibits | filing ↗ |
| 2026-01-20 | OtherExhibits | filing ↗ |
| 2025-12-16 | OtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-05 | 2026-06-03 | 0001193125-26-259488 ↗ |
| 8-K | 2026-06-03 | 2026-06-03 | 0001193125-26-255414 ↗ |
| 8-K | 2026-05-05 | 2026-04-30 | 0001193125-26-206315 ↗ |
| 8-K | 2026-04-30 | 2026-04-30 | 0001193125-26-197921 ↗ |
| 10-Q | 2026-04-30 | 2026-03-31 | 0001628280-26-028929 ↗ |
| 10-K/A | 2026-04-30 | 2025-12-31 | 0001193125-26-197148 ↗ |
| 8-K | 2026-03-26 | 2026-03-26 | 0001193125-26-126671 ↗ |
| 10-K | 2026-03-26 | 2025-12-31 | 0001628280-26-021504 ↗ |
| 8-K | 2026-03-02 | 2026-02-28 | 0001193125-26-084251 ↗ |
| 8-K | 2026-01-20 | 2026-01-16 | 0001193125-26-015592 ↗ |
| 8-K | 2025-12-16 | 2025-12-16 | 0001193125-25-320901 ↗ |
| 8-K | 2025-10-30 | 2025-10-30 | 0001193125-25-258780 ↗ |